Avalon globocare announces its planned acquisition target, senlangbio, has initiated first-in-human clinical trial in recurrent brain cancer

Trial evaluating epha2-targeted car t-cell therapy in recurrent glioblastoma, an urgent and significant unmet medical need with no standard of care treatment option

AVCO Ratings Summary

AVCO Quant Ranking